H.C. Wainwright lowered the firm’s price target on Savara (SVRA) to $6 from $10 and keeps a Buy rating on the shares. The firm questions if Savara will be able to reach its goal of identifying 1,000 patients by the Molbreevi launch.
Maximize Your Portfolio with Data Driven Insights:
- Leverage the power of TipRanks' Smart Score, a data-driven tool to help you uncover top performing stocks and make informed investment decisions.
- Monitor your stock picks and compare them to top Wall Street Analysts' recommendations with Your Smart Portfolio